En español
NIDA

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT)

This 2 stage study will investigate the effectiveness and safety of a combination pharmacotherapy for methamphetamine use disorder.  Stage 1 will include 20 participants with moderate or severe stimulant use disorder who will receive a monthly injection of extended-release depot naltrexone plus once-daily bupropion extended-release tablets for 8 weeks.  If Stage 1 data documents success in at least 3 “responder” study participants, Stage 2 will follow utilizing the same protocol as in Stage 1, to enroll an additional group of 29 participants.

CTN Protocol ID: 
CTN-0054
Enrollment Status: 
Completed
Principal Investigator(s)
Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
lwalter@ucla.edu

Get this Publication

    SAMHSA Treatment Locator

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.